Coherus reports survival data from toripalimab Phase 3 study (NASDAQ:CHRS)


Technician at a laboratory surrounded by lab tools


Coherus Biosciences (NASDAQ:CHRS) reported promising overall survival data from a Phase 3 study for its drug candidate toripalimab in the treatment of an aggressive head and neck cancer.

The study tested toripalimab in combination with the chemotherapy drugs gemcitabine and

Source link

Leave A Reply

Your email address will not be published.